Mobile: +1 908 608 7170
Seqirus news releases
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.1
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health. The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.1
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical studies demonstrating the ability of a MF59® adjuvanted influenza vaccine to increase immune responses when used in both seasonal and pandemic influenza vaccines.
Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
This news release is intended for business and trade media only.
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
New Data on Cell-Based Seasonal Influenza Vaccines
This news release is intended for Health Professional media only.
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older, 1 extending the company's broad portfolio of influenza vaccine offerings. The approval also applies to the trivalent formulation of AFLURIA® (Influenza Vaccine).2
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
New studies highlight health and economic benefits of adjuvanted trivalent influenza vaccine amongst two at-risk populations – 65 years+ and young children
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compared with cell-derived vaccine viruses. The results are reported from a retrospective analysis that evaluated the degree of match between circulating influenza viruses and candidate viruses that were derived from egg-based and cell-based technologies over multiple influenza seasons.1
Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2018-2019 influenza season. Seqirus, one of the largest influenza vaccine companies in the world, and a leading innovator of new technologies, expects to distribute over 50 million doses to the U.S. market this year.
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina. The approval will enable Seqirus to more than double current production levels of FLUCELVAX® QUADRIVALENT for supply in the 2019/20 influenza season.
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older
Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in individuals five years of age and older, extending the company’s broad portfolio of influenza vaccine offerings. AFLURIA QUADRIVALENT, which was first approved in the U.S. on August 2016 for individuals 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.3,10
Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services (DHHS), has requested urgent support to help displaced residents fight the onset of influenza.
Seqirus announces major advances in pandemic preparedness
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season.